loading...| Preferred Name |
Dexverapamil |
|
| Synonyms |
|
|
| Definitions |
The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1563 |
|
| CAS_Registry |
38321-02-7 |
|
| Chemical_Formula |
C27H38N2O4 |
|
| code |
C1563 |
|
| Contributing_Source |
FDA |
|
| definition |
The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms. This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04) |
|
| FDA_UNII_Code |
QR5PYD126V |
|
| in_subset | ||
| label |
Dexverapamil |
|
| Legacy Concept Name |
Dexverapamil |
|
| NCI_Drug_Dictionary_ID |
41269 |
|
| PDQ_Closed_Trial_Search_ID |
41269 |
|
| PDQ_Open_Trial_Search_ID |
41269 |
|
| Preferred_Name |
Dexverapamil |
|
| prefixIRI |
NCIT:C1563 |
|
| prefLabel |
Dexverapamil |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0280858 |
|
| subClassOf |